Esperion Gets FDA OK For Another New Cholesterol-Buster, Offers Financial Update
ANN ARBOR—Esperion Therapeutics Inc. announced U.S. Food and Drug Administration approval of Nexlizet, a combination tablet of Esperion’s new non-staticholesterol reducing drug bempedoic acid and an earlier non-statin cholesterol-reducer, exetimibe. The new drug will be an oral, once-daily, non-statin medicine designed to reduce levels of LDL cholesterol, the so-called bad cholesterol, intended for people who